A financial analysis in Science Translational Medicine finds that two NCATS rare diseases programs have led to reduced cost of developing new drugs and reduced financial risks.
Read up on the success of two NCATS rare diseases therapeutic development programs, how the CTSA program is supporting new ways to improve clinical trial recruitment, and more.
CTSA hubs are forming a national network to overcome barriers to participant recruitment for clinical trials.
ExRNA communication researchers find saliva provides a strong foundation for a noninvasive diagnostic test for stomach cancer.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
NIH research team works with industry to develop treatments for lysosomal storage disorders.
Research team identifies 50+ drugs that may block Ebola infection.
- Notice of Extension of Public Comment Period for Notice of Proposed Rulemaking for Clinical Trials Registration and Results Submission under FDAAA
- Notice of NIH Participation in the Cyber-Physical Systems Initiative (CPS)
- Notice of Extension of the Public Comment Period for NOT-OD-15-019
- More Funding & Notices...
- Multifactorial Analysis of Conditional Reprogramming of Human Keratinocytes • PLOS ONE
- Gene Alterations in Melanoma May Predict Immunotherapy Outcomes • American Association for Cancer Research
- Research in the News: Yale Researchers Devise a Faster, Less Expensive Way to Analyze Gene Activity • Yale University
- More News & Events...
IN THE SPOTLIGHT
NCATS intends to publish funding opportunities for Collaborative Innovation Awards through the Clinical and Translational Science Awards program. See the notices below for details: